linjc16/ctgov huggingface dataset:
Ketamine for Analgesia After Cesarean Section

Study Overview
=================
Brief Summary
-----------------
In this prospective randomized trial, investigators compared the analgesic effect of subanesthetic dose of ketamine versus placebo in parturients undergoing cesarean section under spinal anesthesia.

Detailed Description
-----------------
In this prospective randomized trial, investigators compared the analgesic effect of subanesthetic dose of ketamine versus placebo in parturients undergoing cesarean section under spinal anesthesia. The patients were randomized in two groups: Group Ketamine: these patients recieved 0.25 mg/kg of Ketamin intravenously 5 minutes after the spinal anesthesia. Group Placebo: recieved 20 ml of normal saline solution intravenously 5 minutes after the spinal puncture. The investigators recorded intra demographic, intraoperative and post operative data. The main outcome was the analgesic score: the visual analog scale (VAS). dynamic VAS was also monitored at 24 hours post operatively.

Official Title
-----------------
Ketamine for Analgesia After Cesarean Section

Conditions
-----------------
Postoperative Pain, Cesarean Section

Intervention / Treatment
-----------------
* Drug: 0.25 mg/kg of Ketamine
* Drug: 20ml of normal saline solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: full term pregnant adult patients Monofetal pregnancy scheduled for urgent or elective cesarean section under spinal anesthesia Exclusion Criteria: necessity of general anesthesia during the procedure Post partum hemorrage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ketamine Group<br>Patients recieving 0.25 mg/kg of ketamine 5 minutes after spinal anesthesia | Drug: 0.25 mg/kg of Ketamine<br>* patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia<br>|
| Placebo Comparator: Placebo Group<br> | Drug: 20ml of normal saline solution<br>* 20ml of normal saline solution intravenously 5 minutes after spinal anesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dynamic Visual Analog Scale | Pain score VAS range from 0 to 10, high scores mean worse outcome | 24 hours after cesarean section |
Wound Etiology and Healing Study

Study Overview
=================
Brief Summary
-----------------
The purpose of the WE-HEAL Study is to help researchers use human tissue samples and health records to study the reasons why some patients heal quickly and some have problems healing wounds. All patients seen with an open wound or hidradenitis suppurativa are invited to participate. Information from this research may help to understand how to prevent and treat certain diseases.

Official Title
-----------------
The Wound Etiology and Healing Study

Conditions
-----------------
Wounds, Hidradenitis Suppurativa, Hidradenitis, Acne Inversa

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 Open wound or hidradenitis suppurativa English speaking Able to give informed consent Exclusion Criteria: Non-English speaking. Unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non Healing Ulcer<br> | |
| Hidradenitis suppurativa<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to wound healing | This prospective study will establish a biobank for collection of residual biopsy tissue discarded after debridement, and collection of other biospecimens at the discretion of the investigators including wound fluid and serum samples. Patients will also permit linking of biosamples to clinical outcomes data. Using a primary outcome of wound healing we will compare biomarkers on tissue, serum and wound fluid from patients with non-healing ulcers and hidradenitis to identify angiogenic and vasculogenic pathways that are dysregulated in patients with wound healing problems. | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non healing ulcer, Wound, Hidradenitis suppurativa, Acne Inversa, Hidradenitis
Performance of Pulmonary Embolism Risk Scores Out Come in CTPA Confirmed Patients

Study Overview
=================
Brief Summary
-----------------
Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients. Compare PERFORM score with the currently validated PESI in risk stratification of patients

Detailed Description
-----------------
Pulmonary embolism (PE) is a common and potentially lethal condition in the emergency department requiring early and accurate management. The short-term mortality rate of PE varies widely and ranges from less than 2% in many patients with non massive PE to more than 95% in patients who experience cardiorespiratory arrest. Although several prognostic models of acute PE are currently used, all of them have practical limitations. Of all clinical scores integrating PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) and its simplified version,(sPESI) have been most extensively validated to date. However, current prognostic scores for pulmonary embolism (PE) are partly based on patients without PE confirmation via computed tomographic pulmonary angiography (CTPA), involving subjective parameters and complicated scoring methods [8]. Therefore, an objective, accurate, and simple prognostic model in CTPA-confirmed patients to predict the risk of 30-day mortality. help clinicians assess patients' risks and improve therapeutic decision-making that is called PERFORM score (pulmonary embolism risk score for mortality)

Official Title
-----------------
Performance of Pulmonary Embolism Risk Scores for Assessment of Outcome in Computed Tomographic Pulmonary Angiography Confirmed Patients

Conditions
-----------------
Pulmonary Embolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients above 18 years old with PE confirmed by CTPA are considered for inclusion in the study. Exclusion Criteria: • Patients who have contraindications for CTPA eg. Renal impairment Patients diagnosed and treated as PE without doing CTPA. Patients who refuse to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients. |  | from 11/2022 to 4/2024 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare PERFORM score with the currently validated PESI in risk stratification of patients. |  | from 11/2022 to 4/2024 |
Pharmacokinetics of Misoprostol With Titrated Oral Administration

Study Overview
=================
Brief Summary
-----------------
The AUC240, AUC360, and AUC480 of titrated oral misoprostol are greater than traditional oral misoprostol.

Detailed Description
-----------------
The primary outcomes measures of the study are the area under the curve of serum concentration of misoprostol acid against time up to 240, 360 and 480 minutes.

Official Title
-----------------
Phase 1 Study of Titrated Oral Misoprostol

Conditions
-----------------
Hypotonic; Labor

Intervention / Treatment
-----------------
* Drug: Misoprostol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20-40 Y/O healthy and non-pregnant woman Exclusion Criteria: heart, liver or kidney disease, anaphylaxis to misoprostol

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: hourly misoprostol<br>20 microgram misoprostol intake per hour | Drug: Misoprostol<br>* 20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses<br>* Other names: cytotec;|
| Active Comparator: traditional misoprostol<br>80 microgram misoprostol intake per 4 hours | Drug: Misoprostol<br>* 20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses<br>* Other names: cytotec;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC480 (the area under the curve of serum concentration of misoprostol acid against time up to 480 minutes) |  | 480 min post start of oral misoprostol administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC240 (the area under the curve of serum concentration of misoprostol acid against time up to 240 minutes) |  | 240 min post start of oral misoprostol administration | 
| AUC360 (the area under the curve of serum concentration of misoprostol acid against time up to 360 minutes) |  | 360 min post start of oral misoprostol administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
misoprostol, pharmacokinetics
Role of Subsequent Atrial Tachycardia in Mechanisms of Persistent AF

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators aim to examine the prognostic role of subsequent Atrial Tachycardias (ATs) in the mechanisms of atrial fibrillation (AF). Therefore, the investigators compare patients who were randomly assigned to either undergo cardioversion after AF has been terminated to AT or further ablation until the achievement of sinus rhythm.

Official Title
-----------------
The Prognostic Role of Subsequent Atrial Tachycardias Occurring After Atrial Fibrillation Termination: A Prospective Randomized Trial

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: Catheter ablation of subsequent atrial tachycardia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: persistent AF for at least 1 months, age > 18 years, refractory to drug therapy, no prior ablation Exclusion Criteria: prior AF ablation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A: cardioversion at AT<br>after achievement of AT, pts were cardioverted | |
| Group B: ablation to SR<br>After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination | Procedure: Catheter ablation of subsequent atrial tachycardia<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arrhythmia-free survival |  | 24 months after enrolment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type of Arrhythmia recurrence |  | 24 months after enrolement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrial fibrillation, catheter ablation, subsequent atrial tachycardia, mechanisms
Adrenalectomy for Solitary Adrenal Gland Metastases

Study Overview
=================
Brief Summary
-----------------
The adrenal glands are one of the most common organs involved in metastatic disease. Metastases are the second most common type of adrenal mass, second only to adenomas. It is a frequent finding during autopsy with a reported rate as high as 27% in patients with known primary malignancy. Although several studies have found an increased survival in patients who undergo resection of solitary adrenal metastases the indications for adrenalectomy in cases of metastatic adrenal tumor remain controversial. Collinson et al reported an increased survival in patients with melanoma. Median survival was 16 months for patients who underwent adrenalectomy compared to 5 months for patients with documented adrenal metastases treated non surgically. The aim of this study is to compare retrospectively in case and control study, performing adrenalectomy, open or laparoscopic, versus supportive treatment for patients with solitary adrenal gland metastases. The investigators will review charts of patients between January 1994 and November 2009 who had adrenal gland metastases. The variables the inevstigators will compare are mortality, morbidity, primary tumour sites, histological cell type, age, tumour size, presence of synchronous metastases, mean time from diagnosis of primary tumor to treatment of adrenal metastases, indication for adrenalectomy, partial versus total adrenalectomy, suspected versus confirmed metastatic disease.

Official Title
-----------------
The Use of Adrenalectomy in Patients With Solitary Adrenal Gland Metastases

Conditions
-----------------
Adrenal Gland Metastases, Adrenalectomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metastatic disease to the adrenal gland Exclusion Criteria: Primary adrenal neoplasm
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adrenalectomy improves overall survival in patients with solitary metastasis | Survival data compared to historic controls | 25 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adrenalectomy can be performed with minimal morbidity in patients with metastatic lesions to the adrenal gland. | Operative outcomes compared to historic control patients undergoing adrenalectomy for non-maligant disorders. | 25 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adrenalectomy, metastasis, morbidity, mortality, survival
Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Study Overview
=================
Brief Summary
-----------------
This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.

Official Title
-----------------
Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Conditions
-----------------
Type 3 Choroidal Neovascularization

Intervention / Treatment
-----------------
* Drug: Aflibercept


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females aged more than 50 years Patients with type 3 choroidal neovascularization assessed on FA, ICG and OCT Exudation on SD-OCT scans defined by intraretinal cysts or subretinal fluid. Best Corrected Visual Acuity at inclusion between 24 and 78 letters (ETDRS) Media clarity, pupillary dilation and patient cooperation sufficient to allow fundus photographs of adequate quality Exclusion Criteria: Any contraindications as reported in the labelling of Aflibercept (Eylea®): Ocular or periocular infection, Active intraocular inflammation or Hypersensitivity. Any previous history of intravitreal injections in the study eye for exudative AMD Any secondary chorioretinal anastomosis due to retinal scar or fibrosis Any history of vitrectomy Media opacities preventing accurate imaging of the retina (cataract) Any other retinal disorder possibly associated with type 3 CNV (epiretinal membrane, macular hole) Confirmed intraocular pressure ≥25 mmHg or non-stable glaucoma.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aflibercept<br> | Drug: Aflibercept<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline in Best Corrected Visual Acuity (BCVA) | Mean change from baseline in Best Corrected Visual Acuity (BCVA) as measured by ETDRS letter score at 4 meters | 52 weeks |
Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

Study Overview
=================
Brief Summary
-----------------
Expanded access use of INCB052793 to treat a single patient with Myelofibrosis.

Intervention / Treatment
-----------------
* Drug: INCB052793


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: -

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: INCB052793|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Forecasting ED Overcrowding With Statistical Methods: A Prospective Validation Study

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to prospectively validate statistical forecasting tools that have been widely used retrospectively in forecasting ED overcrowding

Detailed Description
-----------------
Emergency department (ED) overcrowding is a chronic international issue that has been repeatedly associated with detrimental treatment outcomes such increased 10-day-mortality. Forecasting future overcrowding would enable pre-emptive staffing decisions that could alleviate or prevent overcrowding along with its detrimental effects. Over the years, several predictive algorithms have been proposed ranging from generalized linear models to state space models and, more recently, deep learning algorithms. However, the performance of these algorithms has only been reported retrospectively and the clinically significant accuracy of these algorithms remains unclear. In this study the investigators aim to investigate the accuracy of the previously reported ED forecasting algorithms in a prospective setting analogous to the way these tools would be used if used implemented as a decision-support system in a real-life clinical setting.

Official Title
-----------------
Forecasting ED Overcrowding With Statistical Methods: A Prospective Validation Study

Conditions
-----------------
Emergencies

Intervention / Treatment
-----------------
* Other: Early warning system for emergency department overcrowding


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients presenting in the Emergency Department Exclusion Criteria: No exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Early warning system for emergency department overcrowding|In this study, no interventions are performed.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Next day overcrowding | A day is defined as overcrowded if daily peak occupancy exceeds 80 patients, and severely overcrowded if daily peak occupancy exceeds 100 patients. | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of hourly arrivals in the ED 24 hours ahead |  | 24 hour | 
| Hourly occupancy in the ED 24 hours ahead |  | 24 hour | 
| Number of daily arrivals in the ED 7 days ahead |  | 24 hour | 
| Daily peak occupancy in the ED 7 days ahead |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
emergency department, overcrowding, forecasting, artificial intelligence, deep learning
Telephone and Mail Intervention for Alcohol Use Disorders

Study Overview
=================
Brief Summary
-----------------
Randomized controlled trial and benefit-cost study of a telephone and mail intervention for non-treatment-seeking primary care patients with alcohol abuse or dependence

Official Title
-----------------
Telephone and Mail Intervention for Alcohol Use Disorders

Conditions
-----------------
Alcohol Use Disorders

Intervention / Treatment
-----------------
* Behavioral: telephone counseling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: primary care patients with DSM-IV alcohol abuse or dependence Exclusion Criteria: pregnancy suicidality alcohol treatment in prior 3 months

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: telephone counseling|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported alcohol consumption in the prior 28 days |  |  | 
| Number of risky drinking days in the prior 28 days |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health care utilization |  |  | 
| car crashes |  |  | 
| criminal justice system involvement |  |  |